
Opinion|Videos|January 24, 2024
The Evolving Treatment Landscape in Relapsed/Refractory CLL
Author(s)Mazyar Shadman, MD, MPH
Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5








































